Cala Health, Inc., a San Francisco, CA-based bioelectronic medicine company developing wearable therapies for chronic disease has raised $50 million in Series C funding. New investors in the Series C funding round include Novartis, Baird Capital, LifeSci Venture Partners, TriVentures, and others. All existing investors participated in the round, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital, and
Read More
bioelectronic medicines
Verily, GlaxoSmithKline Partner to Develop Bioelectronic Medicines
Alphabet company Verily (formerly Google Life Sciences) is teaming up with pharmaceutical firm GlaxoSmithKline to develop bioelectronic medicines. The new company, Galvani Bioelectronics headquartered in the UK aims to research, develop and commercialize implantable, miniature devices which could potentially treat illnesses such as arthritis, diabetes and asthma. As part of the agreement, GSK will hold 55% equity interest and Verily will hold 45% owned by Verily, and receive up to $712M funding
Read More
